TrioxBio

Nitric Oxide Synthase Inhibitors

Health Tech & Life Sciences
Non Active, Jan 2022 ceased to operate
Pre-Funding Bnei Brak, Israel Founded 2015
LinkedIn
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2015
Headcount
1
HQ
Bnei Brak, Israel
Sector
Health Tech & Life Sciences

About

TrioxBio develops and commercializes proprietary synthetic small molecules to treat pathologic states caused by the overproduction of nitric oxide. The company's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a nitric oxide synthase (NOS) inhibitor that blocks the production of nitric oxide, preventing the dilation of blood vessels and other detrimental effects caused by excessive NOS activity. TrioxBio's leading candidate, MTR-107 (indicated for the prevention of recurrent intradialytic hypotension), received orphan drug designation from the FDA in August 2016. In addition, its development program received fast-track designation from the FDA in May 2018. The company has applied to the FDA for two orphan drug designations for vasoplegic syndrome and intradialytic hypotension, and the request has been approved for intradialytic hypotension. As part of SK Pharma Group, TrioxBio is involved in the R&D of treatments in the areas of oncology, antiviral diseases, and new drug-delivery systems.

Q&A

What is TrioxBio's primary focus?
TrioxBio develops and commercializes proprietary synthetic small molecules to treat pathologic states caused by the overproduction of nitric oxide.
What is the status of TrioxBio?
TrioxBio is currently inactive, having ceased operations in January 2022.
When was TrioxBio founded?
TrioxBio was founded in July 2015.
What is TrioxBio's leading drug candidate?
TrioxBio's leading candidate is MTR-107, indicated for the prevention of recurrent intradialytic hypotension.
Has MTR-107 received any special designations from the FDA?
Yes, MTR-107 received orphan drug designation from the FDA in August 2016 and fast-track designation in May 2018.
Who are the co-founders of TrioxBio?
The co-founders of TrioxBio are Shlomo Sadoun, who also served as CEO, and Roy Farfara.
What is TrioxBio's primary sector?
TrioxBio's primary sector is Health Tech & Life Sciences.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsdrug-discoverydrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)